Skip to main content

Table 7 Multivariable analysis for the association of baseline factors with BCR-free survival

From: PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy

  No. of patients Hazard ratio 95% CI p value*
Clinical data
 Age, no., n = 186
  Continuous   1.030 0.991–1.071 0.133
 iPSA, no., n = 184
  Continuous   1.024 1.005–1.043 0.014
  Pathological data     
 Gleason score in surgical specimen, no., n = 186
  6–7 133 Reference   
  8–10 53 3.253 1.779–5.950  < 0.001
 pT status, no., n = 186
  2 92 Reference   
  3 94 1.471 0.773–2.797 0.239
 pN status, no., n = 186
  No LN metastasis 154 Reference   
  With LN metastasis 32 1.027 0.418–2.525 0.954
 Surgical margin, no., n = 180
  Negative 152 Reference   
  Positive 28 1.539 0.716–3.305 0.269
Imaging parameters     
 miT status from PSMA PET, no., n = 186
  2 125 Reference   
  ≥ 3a 61 1.941 1.047–3.599 0.035
 miN status from PSMA PET, no., n = 186
  No LN metastasis 168 Reference   
  With LN metastasis 18 1.233 0.389–3.908 0.722
 SUVmean, no., n = 183
  Continuous   0.743 0.491–1.123 0.159
 SUVmax, no., n = 183
  Continuous   1.202 0.943–1.532 0.137
 TV
  Continuous   0.934 0.883–0.988 0.017
  1. BCR biochemical recurrence, CI confidence interval, iPSA initial PSA, LN lymph node, PET positron emission tomography, PSA prostate-specific antigen, PSMA prostate-specific membrane antigen, SUV standardized uptake value, TV tumor volume
  2. *Significant associations are given in bold